CDFD-incubated Acubiosys harnesses AI for psoriasis, diabetic inflammation drugs

Hyderabad-based start-up Acubiosys, incubated at the Centre for DNA Fingerprinting and Diagnostics (CDFD), has launched AI-driven, nanotechnology-enabled plant-based medicines for psoriasis and diabetic inflammation.

Hyderabad: Here is a classic example of how Artificial Intelligence (AI) can be used to identify active compounds and develop treatments for diseases.

A start-up Acubiosys incubated in Hyderabad-based Centre for DNA Fingerprinting and Diagnostics (CDFD) has utilised AI technology and launched medications for treatment of psoriasis (skin disorder) and complications arising out of chronic diabetic inflammation.

---

The biotechnology start-up has successfully integrated Artificial Intelligence (AI) and nanotechnology to develop next-generation plant-based medicines for chronic skin disorders and wound management.

It deployed advanced AI algorithms to scan massive botanical databases and utilized 3D molecular modeling to virtually screen thousands of plant compounds. Through this, the researchers were able to predict exactly which molecules and combinations would best target and treat complex conditions like psoriasis, dermatitis, and chronic diabetic inflammation.

The startup has successfully commercialized two patented, nanotechnology-enabled topical formulations. The company has manufactured two products in India, including BOCUGL, for management of psoriasis, dermatitis, and melasma and AZBECO, an advanced wound care formulation for diabetic foot ulcers.

According to CDFD, the products have been manufactured under strict Good Manufacturing Practices (GMP) and AYUSH regulatory compliance. The underlying technology platforms have already been filed for patents across global jurisdictions, including India, China, and the United States, CDFD said.

The integration of nanotechnology plays a critical role in the delivery mechanism of these therapies. By encapsulating the AI-optimized plant active ingredients into microscopic particles, the formulations easily bypass the skin’s tough outer barrier, delivering the therapeutic compounds directly to deep, inflamed tissues, researchers said.

Dr. Srinivas Maddi, Founder and CEO of Acubiosys Private Limited, said, “leveraging the world-class R& D infrastructure at CDFD Technology Incubator was instrumental in conducting critical preclinical and animal studies to validate the technology.”